Cleared Traditional

K896046 - VITAPATCH CATH. SECUREMENT DEVICE W/CHLORHEXIDINE (FDA 510(k) Clearance)

Class I General Hospital device.

K896046 · Vitaphore Corp. · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 1990
Decision
86d
Days
Class 1
Risk

K896046 is an FDA 510(k) clearance for the VITAPATCH CATH. SECUREMENT DEVICE W/CHLORHEXIDINE. Classified as Device, Intravascular Catheter Securement (product code KMK), Class I - General Controls.

Submitted by Vitaphore Corp. (Menlo Park, US). The FDA issued a Cleared decision on January 11, 1990 after a review of 86 days - a notably fast clearance cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5210 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Vitaphore Corp. devices

Submission Details

510(k) Number K896046 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 17, 1989
Decision Date January 11, 1990
Days to Decision 86 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
42d faster than avg
Panel avg: 128d · This submission: 86d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code KMK Device, Intravascular Catheter Securement
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 880.5210
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.